Serum Galectin-3 Levels in Patients with Hepatocellular Carcinoma, Liver Cirrhosis and Chronic Viral Hepatitis

2018 ◽  
Vol 70 (1) ◽  
pp. 132-139
Author(s):  
Mohammed K. Zahra ◽  
Taher E. Attia ◽  
Amira Y. Ahmad
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Galectin 3

Increased levels of typically fetal bile acid species in patients with hepatocellular carcinoma

2001 ◽  
Vol 100 (5) ◽  
pp. 499-508 ◽  
Author(s):  
Mohamad Y. EL-MIR ◽  
Maria D. BADIA ◽  
Nazaret LUENGO ◽  
Maria J. MONTE ◽  
Jose J. G. MARIN
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Liver Metastasis ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Control Group ◽  
Serum Alpha Fetoprotein ◽  
Liver Neoplasia ◽  
Urine And Serum ◽  
Serum And Urine

The aim of this work was to investigate the reappearance during liver neoplasia of bile acids (BAs) species, which are unusual in healthy adults, but common in fetuses. Serum and urine samples were collected from patients with hepatocellular carcinoma (HCC; n = 27), and for comparative purposes, with liver cirrhosis (n = 49), liver metastasis (n = 19), chronic viral hepatitis (n = 11) and healthy volunteer (control group; n = 26) groups. BAs were identified and measured by GC–MS. Hypercholanaemia was found in all groups of patients. In HCC, this was characterized by a marked increase in the chenodeoxycholate/cholate ratio in both serum and urine. Although increased levels of BAs, with hydroxylations at unusual positions, and oxo-BAs were found in HCC, these were not significantly different from those observed in other groups. However, BAs with a flat structure, i.e. Δ4-unsaturated- and 5α- or allo-BAs, which were almost absent in healthy subjects, were markedly increased in the serum and urine of HCC patients. They were also detected, although in much lower amounts, in liver metastasis and liver cirrhosis, but not in viral hepatitis. Flat-BAs were better detected in urine than in serum. Urinary Δ4-unsaturated-BA output was significantly lower in patients with small tumours (< 3 cm) compared with those with higher size tumours. No correlation between flat-BA output into urine and serum alpha-fetoprotein or total BAs was found. These results suggest that Δ4- and/or allo-BAs are particularly elevated in patients with HCC, which may be a potentially useful complementary, rather than alternative, marker for early detection of liver neoplasia.

scholarly journals ESTRATEGIAS PARA LA ERRADICACIÓN MUNDIAL DE LA HEPATITIS VIRAL CRÓNICA PARA EL 2030

2020 ◽  
Vol 5 (4) ◽  
pp. 45
Author(s):  
Edgardo Mengual-Moreno ◽  
Maribel Lizarzábal-García ◽  
Orlando J. Penaloza
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Diagnostic Methods ◽  
World Health ◽  
Post Exposure Prophylaxis ◽  
Hepatitis D

Los virus de hepatitis B (VHB), C (VHC) y D (VHD); producen hepatitis viral crónica (HVC) responsable de 1.4 millones de muertes por cirrosis hepática y carcinoma hepatocelular. La Organización Mundial de la Salud, adoptó estrategias para la eliminación del VHC para el año 2030. La vacunación contra el VHB reduce el 80% de muertes, previene la HVC por VHB, VHD y el carcinoma hepatocelular. La prevención de la transmisión vertical es una estrategia 90% útil para detener la HVC en hijos de madres infectadas con el VHB. El uso apropiado de inyecciones, pesquisaje adecuado de la sangre de dotantes y la selección restrictiva de donantes disminuye el riesgo de VHC. Las medidas de reducción de daño de HVC consisten en proporcionar jeringas estériles a adictos, prevención de accidentes por pinchazos en personal de salud, introducción de dispositivos de seguridad para la prevención de lesiones punzantes, vacunación de todos los trabajadores de la salud y profilaxis posterior a accidentes laborales. El diagnóstico correcto de VHB permitirá instaurar el tratamiento disponible no curativo, mientras que la terapia antiviral de acción directa cura la hepatitis C. El uso de preservativos y nuevos métodos diagnósticos podrían ser estrategias útiles de prevención de HVC. Palabras claves: hepatitis B, hepatitis C, hepatitis D, hepatitis viral crónica, cirrosis hepática, erradicación. ABSTRACT Chronic viral hepatitis (CVH) associated with Hepatitis B (HBV), C (HCV) and D (HDV) viruses are responsible for 1.4 million deaths from liver cirrhosis and hepatocellular carcinoma. The World Health Organization has implemented strategies for the elimination of HCV by 2030. Vaccination against HBV reduces 80% of deaths and prevents CVH associated with HBV, HDV, and hepatocellular carcinoma. The prevention of perinatal vertical transmission is the most appropriate strategy to avoid CVH by 90% in children of HBV infected mothers. The use of injections appropriately, the screening of blood from donors, and restrictive donor selection decrease the risk of HCV. CVH harm reduction consist of providing sterile syringes to people who inject drugs (PWID), prevention of accidental puncture in health personnel, introduction of safety devices for the prevention of puncture injuries, vaccination against HBV of all health workers and post-exposure prophylaxis after work related accidents. The correct diagnosis of HBV, will allow the introduction of available non-curative treatment, while direct-acting antiviral therapy cures hepatitis C. The use of condoms and new diagnostic methods could be useful strategies for preventing HCV. Keywords: hepatitis B, hepatitis C, hepatitis D, chronic viral hepatitis, liver cirrhosis, eradication.

scholarly journals The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma

2021 ◽  
Author(s):  
Cortlandt M. Sellers ◽  
Johannes Uhlig ◽  
Johannes M. Ludwig ◽  
Jeffrey S. Pollak ◽  
Tamar H. Taddei ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Prognostic Value ◽  
Chronic Viral Hepatitis ◽  
Inflammatory Biomarkers

Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma

2009 ◽  
Vol 150 (1) ◽  
pp. 19-26 ◽  
Author(s):  
Alajos Pár
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis B ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Mivel a hepatitis B- és C-vírus- (HBV-, HCV-) fertőzés döntő szerepet játszik a hepatocellularis carcinoma (HCC) keletkezésében, a HBV és HCV okozta hepatitis és cirrhosis megelőzése és kezelése egyben a HCC prevencióját is jelentheti. A HCC primer prevencióját képviseli a HBV elleni vakcináció és a donorok szűrése HBV- és HCV-markerekre. A szekunder prevencióhoz sorolható az interferonalapú és/vagy nukleozidanalóg anti-HBV- és anti-HCV-terápia, a cirrhosisos betegek HCC irányában történő alfa-foetoprotein + ultrahang szűrése, valamint a HCC kuratív reszekciója/ablatiója utáni adjuváns antivirális kezelés. Várható, hogy a HBV-vakcináció világszerte történő széles körű alkalmazása, továbbá az optimalizált individuális antivirális kezelésmódok, az új nukleozidanalógok és HCV-specifikus proteáz- és polimerázgátlók révén előrelépés történik nemcsak a vírushepatitisek megelőzésében és terápiájában, hanem a HCC prevenciójában is a nem túl távoli jövőben.

Portal vein thrombosis as a complication of coronavirus infection against the background of chronic viral hepatitis

2021 ◽  
Vol 2 (88) ◽  
pp. 66-70
Author(s):  
A.V. Kuznetsova ◽  
◽  
A.V. Ivolgina ◽  
Ye.V. Dubotolkina ◽  
T.Ye. Makarova ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Hepatitis C ◽  
Portal Vein ◽  
Viral Hepatitis ◽  
Abdominal Ultrasound ◽  
Chronic Viral Hepatitis ◽  
Outpatient Basis ◽  
Vein Thrombosis ◽  
Viral Hepatitis C ◽  
Coronavirus Infection

The article presents an extract from an outpatient case history card of a 47-year-old patient observed at the Central Hospital for Chronic Hepatitis C. In 2017, he received a course of therapy for this disease (Pegasis in combination with ribavirin). A sustained virological response (SVR) has been achieved. According to elastometry data dated 12/13/2017 – the degree of fibrosis F4 Metavir, 13.1 KPa. In January 2021, he suffered a coronavirus infection (according to the CT scan of the lungs, the lesion was 20 %). The disease proceeded against the background of chronic viral hepatitis C complicated by liver cirrhosis. He was treated symptomatically on an outpatient basis. He did not receive anticoagulant therapy. In February 2021, abdominal ultrasound (ABP) revealed a thrombus in the portal vein. The presence of a thrombus in the portal vein contributes to the further progression of liver cirrhosis

Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma

2003 ◽  
Vol 3 (8) ◽  
pp. 1169-1176 ◽  
Author(s):  
G Rasi ◽  
P Pierimarchi ◽  
P Sinibaldi Vallebona ◽  
F Colella ◽  
E Garaci
Keyword(s):  
Hepatocellular Carcinoma ◽  
Combination Therapy ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Thrombopoietin levels in serum and liver tissue in patients with chronic viral hepatitis and hepatocellular carcinoma

2000 ◽  
Vol 99 (3) ◽  
pp. 207-214 ◽  
Author(s):  
Michiko OKUBO ◽  
Goshi SHIOTA ◽  
Hironaka KAWASAKI
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Liver Diseases ◽  
Total Mass ◽  
Sandwich Elisa ◽  
Chronic Viral Hepatitis ◽  
Rt Pcr ◽  
Platelet Counts ◽  
Indocyanine Green Test ◽  
Normal Controls

Thrombocytopenia in liver diseases is considered to be due to splenic platelet pooling and accelerated destruction. Since thrombopoietin (TPO), a regulator of thrombopoiesis, is produced mainly in the liver, decreased production of TPO may account for thrombocytopenia in liver diseases. To address this issue, we measured serum TPO, using a sensitive sandwich ELISA, in 108 patients with chronic viral hepatitis, which included chronic hepatitis (CH) and liver cirrhosis (LC), and hepatocellular carcinoma (HCC), and in 29 normal controls. TPO mRNA in 78 liver samples was examined by reverse transcription (RT)-PCR. Platelet counts in CH, LC, HCC and controls were 176±15×109/l, 81±8×109/l, 99±7×109/l and 234±9×109/l respectively. Serum TPO levels in CH, LC and HCC were 2.79±0.4 fmol/ml, 1.49±0.2 fmol/ml and 1.97±0.2 fmol/ml, and were higher than those of controls. Serum TPO levels were positively correlated with prothrombin time and serum albumin (P < 0.05, in each case), and negatively correlated with Indocyanine Green test and Pugh score (P < 0.01 and P < 0.05 respectively). However, RT-PCR and immunohistochemistry showed that expression of TPO mRNA and protein were similar in the different liver diseases, suggesting that serum TPO is a reflection of the total mass of functional liver. Platelet counts were negatively correlated with spleen index, but not with serum TPO. These results suggest that thrombocytopenia in liver disease is not directly associated with serum TPO but is associated with hypersplenism.

scholarly journals Hepatocellular carcinoma (HCC); aetiological considerations

2015 ◽  
Vol 1 (1) ◽  
pp. 18 ◽  
Author(s):  
Omar Abdel-Rahman
Keyword(s):  
Hepatocellular Carcinoma ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis

Hepatocellular carcinoma (HCC) is a commonly occurring cancer worldwide. The aetiology of HCC, often associated with different molecular carcinogenic pathways, differs geographically; with chronic viral hepatitis being the main cause in most localities. Different driving mutations resulting from distinct carcinogenic pathways potentially impact the choice of effective therapies for HCC.

scholarly journals Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?

2022 ◽  
Vol 23 (1) ◽  
pp. 500
Author(s):  
Francesco Paolo Russo ◽  
Alberto Zanetto ◽  
Elisa Pinto ◽  
Sara Battistella ◽  
Barbara Penzo ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Viral Hepatitis ◽  
Chronic Viral Hepatitis ◽  
Virological Suppression ◽  
Risk Patients ◽  
Related Liver Disease ◽  
Direct Acting ◽  
Cell Signaling Pathways

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related death. Although the burden of alcohol- and NASH-related HCC is growing, chronic viral hepatitis (HBV and HCV) remains a major cause of HCC development worldwide. The pathophysiology of viral-related HCC includes liver inflammation, oxidative stress, and deregulation of cell signaling pathways. HBV is particularly oncogenic because, contrary to HCV, integrates in the cell DNA and persists despite virological suppression by nucleotide analogues. Surveillance by six-month ultrasound is recommended in patients with cirrhosis and in “high-risk” patients with chronic HBV infection. Antiviral therapy reduces the risks of development and recurrence of HCC; however, patients with advanced chronic liver disease remain at risk of HCC despite virological suppression/cure and should therefore continue surveillance. Multiple scores have been developed in patients with chronic hepatitis B to predict the risk of HCC development and may be used to stratify individual patient’s risk. In patients with HCV-related liver disease who achieve sustained virological response by direct acting antivirals, there is a strong need for markers/scores to predict long-term risk of HCC. In this review, we discuss the most recent advances regarding viral-related HCC.

Sign in / Sign up

Export Citation Format

Share Document